Chenying Guo
Senior Director, Translational Biology @ GondolaBio
About
I am a strategic scientific leader with cross-sector expertise in discovery, translational, and clinical biomarkers in multiple therapeutic areas with a focus on retinal, neurological and autoimmune disorders. I specialize in developing innovative translational strategies and biomarker roadmaps to accelerate the translation of discoveries to the clinic focusing on clinical translatability and therapeutic success. I am passionate about driving scientific innovation and transforming discoveries into meaningful therapies for patients. Throughout my career, I've had the privilege to advance over 10 programs from discovery through clinical development. My leadership philosophy centers on collaboration, scientific rigor, and strategic vision to advance groundbreaking therapies and improve patient outcomes. Let’s connect and explore how we can bring transformative therapies to patients together.
United States
Burlingame
Pharmaceuticals
Translational Medicine, Preclinical development, Clinical biomarkers, Biomarker Discovery, Clinical PoC & PoM, Clinical PoC, Bioanalytical assays, Good Laboratory Practice (GLP), Biomarker disocvery, Bioanalytical analysis, Liver Transplant, multi-omics, MASH, Vision Science, Inflammation, Biology, Multiple Therapeutic Areas, Neurodegeneration, Neuroscience, Biotechnology
Experience
Senior Director, Translational Biology
GondolaBio
California, United States
- Leading translational medicine and clinical biomarker strategies for renal and neuro programs, with a focus on advancing pre-IND assets through Phase 1–2 development and achieving clinical proof-of-concept. - Collaborating with U.S. and Asia teams to develop first-in-human (FIH) trial plans, prepare regulatory documents, onboard CROs, implement Clin Dev, biomarker plans and sample and data management.
Senior Director, Translational Sciences
Pioneering Medicines
Cambridge, Massachusetts, United States
Led translational and biomarker research, clinical biomarker strategies and team and capability development across liver and CNS programs from early discovery through IND-enabling (small molecule, siRNA, cell therapy).
Associate Director, Retina Discovery
Johnson & Johnson Innovative Medicine
Brisbane, California, United States
Led translational pharmacology, biomarker research and assays for retinal disease programs from discovery through phase 1-2 (siRNA, peptide, AAV).
Director, Biomarker Research
Annexon Biosciences
South San Francisco, California, United States
• Accountable for IND-enabling translational strategies and clinical biomarkers for a pipeline spanning autoimmune, CNS and retinal diseases (preclinical through clinical phase 1/2/3) (antibodies, small molecule). • Co-led NextGen drug discovery initiatives with the Head of Research, including indication expansion, targets selection, CI landscape evaluation and program design.
Investigator I to III
Novartis
Cambridge, United States
Investigator III (Dec, 2019– Jul, 2021) Investigator II (Feb. 2017– Dec. 2019) Investigator I (Dec. 2013– Feb. 2017) • Spearheaded a human-centric drug discovery strategy for glaucoma neuroprotection • Established translational models and research capabilities for neuroprotective & anti-inflammatory therapeutic development • Advanced multiple retinal portfolio programs through lead optimization or pre-IND as the Program Team Lead • Led initiatives on targeted intraocular drug delivery and sustained drug release • Served as board member of ophthalmology in vivo council
Postdoctoral Research Fellow
Harvard Medical School
Greater Boston Area
• Investigated intrinsic mechanisms regulating neuronal survival and axonal regeneration in the adult mammalian retina. o Patent US20140128322A1/WO2012118796A1: Compositions for Controlling Neuronal Outgrowth o Patent US10842849B2: Methods for promoting neuronal outgrowth by insulin-like growth factor binding protein-like 1 (IGFBPL1) in glaucoma or leber's optic neuropathy • Conducted phenotypic screening of compounds promoting neuronal cell survival/regeneration • Investigated epigenetic mechanisms controlling the photoreceptor cell degeneration.
Graduate research assistant
UCLA
Los Angeles
• Synaptic neurotransmitter release from the horizontal cells in the mammalian retina. • Laser capture microdissection of retinal cells and analyses.
Education
UCLA
Neurobiology and Neurophysiology
Chenying Guo's Contact Information
Phone
Find the Right Leads
Find Verified Contact Data
What LeadContact does well
Find verified emails, phone numbers, and decision-makers with 98% accuracy.
Find Leads
Find the right people by company, role, industry, location, and more.
925M+ professional profiles
Find Emails
Access verified email addresses for your target contacts.
657M+ emails
Find Phone Numbers
Get cross-validated phone data from multiple top sources.
239M+ phone numbers
More Accurate. Lower Cost.
Find contact data in 1 tool with 98% accuracy
LeadContact integrates leading enrichment tools to deliver more accurate contact data—without paying for each one.
Great conversations start with the right contact.
It’s time to find yours.